NCT03922776 2026-03-18
TILsOV
Centre Oscar Lambret
Phase NA Terminated
Clinical Trials
25 trialsNCT04016142 2026-03-18
ACCRAPAN
Centre Oscar Lambret
Phase 2 Terminated
NCT00421096 2026-03-13
GEMCOL
Centre Oscar Lambret
Phase 2 Terminated
NCT01641484 2026-03-13
ANOXICOL
Centre Oscar Lambret
Phase NA Terminated
NCT04729387 2026-03-13
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Novartis
Phase 3 Terminated
NCT04651127 2026-03-10
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
Sun Yat-sen University
Phase 1/2 Terminated
NCT05159050 2026-02-25
Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis
University of Iowa
Phase 1 Terminated
NCT06171789 2026-02-25
PRO1107 in Patients With Advanced Solid Tumors
Genmab
Phase 1/2 Terminated
NCT06625515 2026-02-24
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Phase 1 Terminated
NCT06546553 2026-02-23
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Pfizer
Phase 1 Terminated
NCT04780945 2026-02-17
FAB
Leiden University Medical Center
Phase 2 Terminated
NCT05756907 2026-02-03
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
Sonnet BioTherapeutics
Phase 1/2 Terminated
NCT06457997 2026-01-29
A Study of PHN-010 in Patients With Advanced Solid Tumors
Pheon Therapeutics
Phase 1 Terminated
NCT05357027 2026-01-21
HPV16 E6 TCR T Cells for Cervical Carcinoma
TCRCure Biopharma Ltd.
Phase 1/2 Terminated
NCT04260802 2026-01-12
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Phase 1/2 Terminated
NCT05082025 2026-01-09
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05194072 2026-01-09
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Seagen Inc.
Phase 1 Terminated
NCT05481645 2026-01-09
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Terminated
NCT06478862 2026-01-09
Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy
Lipomedix Pharmaceuticals Inc.
Phase 2 Terminated
NCT02948426 2026-01-08
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01048853 2026-01-07
Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer
M.D. Anderson Cancer Center
Phase NA Terminated
NCT03746431 2026-01-07
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Fusion Pharmaceuticals Inc.
Phase 1 Terminated
NCT03189108 2026-01-02
Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors
National Institutes of Health Clinical Center (CC)
Terminated
NCT05458960 2025-12-26
BASICS
Washington University School of Medicine
Phase NA Terminated
NCT04000477 2025-12-23
ENDOCOL
University Hospital, Lille
Phase NA Terminated